SL Science Holding Ltd. has submitted an orphan drug designation request to the FDA for its γδ T-cell therapy product, Vδ2+ γδ T cells, for the treatment of glioblastoma multiforme.
Focal adhesion kinase (FAK), a key mediator of cell adhesion and migration, is frequently upregulated in glioblastoma (GBM), where its activity has been associated with increased tumor invasiveness and disease aggressiveness.
Two papers published in the July 1, 2026, issues of Nature and Nature Cancer have reported on preclinical and early clinical data with glycoprotein nonmetastatic melanoma protein B (GPNMB)-targeting CAR T cells in two separate solid tumor types.
Phoremost Ltd. has unveiled its lead program, PMC-001, a next-generation, small-molecule microtubule-targeting agent (MTA) for primary and secondary brain cancers. PMC-001 is a highly differentiated, orally bioavailable MTA.
Far beyond indications like breast cancer, there are sex differences in incidence across a broad range of tumor types. Particularly in glioblastoma, there is a clear male-biased incidence compared to females. The mechanisms that drive this difference are not well understood, buy may include an androgen-related immune response. Recent evidence suggests a key role for androgens in antitumoral immunity and their impact on the response to immune checkpoint inhibitor therapy.
Insilico Medicine Cayman Topco has nominated ISM-0387, an MTA-cooperative protein arginine methyltransferase 5 (PRMT5) inhibitor, as a preclinical developmental candidate for glioblastoma. The discovery and optimization process for ISM-0387 was powered by Chemistry42, Insilico’s generative chemistry platform integrated with over 40 generative AI models.
Previous work showed that neurogenic transcriptional factors, such as NeuroD1 and Neurogenin 2, and small-molecule cocktails can reprogram glioma cells into neuron-like cells while also suppressing their proliferative and invasive phenotypes.
Researchers at the University of Edinburgh are pioneering a cancer therapy that destroys tumors from within while reawakening the immune system, using synthetic super-enhancers (SSEs) to drive targeted killing and durable protection against recurrence. The work builds on a decade of research focused on how glioblastoma stem cells (GSCs) sustain their aggressive cancer identity.
